肿瘤细胞治疗研究
英文原题：Immunotherapy in breast cancer: an overview of current strategies and perspectives.
免疫生物学的最新进展为成功增强针对乳腺癌的宿主免疫铺平了道路。
免疫生物学近期进展推动了增强宿主免疫力、对抗乳腺癌的成功实践。在三阴性乳腺癌中，以PD-1/PD-L1免疫检查点抑制剂为基础的癌症免疫疗法联合化疗，在晚期和早期III期临床试验中均有效。这些令人鼓舞的结果促使免疫检查点抑制剂首次获批用于三阴性乳腺癌，为侵袭性肿瘤和难治人群提供了新的治疗可能。此外，多项正在进行的试验正在调查免疫检查点抑制剂联合常规疗法，以及联合癌症疫苗、CAR-T细胞、双特异性抗体和溶瘤病毒等其他免疫治疗策略，用于所有乳腺癌亚型。本综述概述目前处于临床开发阶段的免疫疗法，并更新临床试验关键结果。最后，本文讨论在乳腺癌管理中成功实施免疫治疗所面临的挑战，以及这些挑战对未来临床试验设计的影响。
Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting phase 3 clinical trials. These encouraging results lead to the first approvals of immune checkpoint inhibitors in triple-negative breast cancer and thus offer new therapeutic possibilities in aggressive tumors and hard-to-treat populations. Furthermore, several ongoing trials are investigating combining immunotherapies involving immune checkpoint inhibitors with conventional therapies and as well as with other immunotherapeutic strategies such as cancer vaccines, CAR-T cells, bispecific antibodies, and oncolytic viruses in all breast cancer subtypes. This review provides an overview of immunotherapies currently under clinical development and updated key results from clinical trials. Finally, we discuss the challenges to the successful implementation of immune treatment in managing breast cancer and their implications for the design of future clinical trials.
MEMBER ACCOUNT
登录成功会直接打开下一页。
